Reach Us +44-1647-403003
Molecular Background of Cancer Recurrence | OMICS International | Abstract
ISSN: 2471-8556

Oncology & Cancer Case Reports
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Review Article

Molecular Background of Cancer Recurrence

Kldiashvili Ekaterina* and Bokuchava Lana

New Vision University, Evgeni Mikeladze St, Tbilisi 0159, Georgia

*Corresponding Author:
Kldiashvili Ekaterina
New Vision University, Evgeni Mikeladze
St, Tbilisi 0159, Georgia
Tel: +995 322 42 44 40
E-mail: [email protected]

Received Date: March 26, 2017 Accepted Date: July 28, 2017 Published Date: July 31, 2017

Citation: Ekaterina K, Lana B (2017) Molecular Background of Cancer Recurrence. Oncol Cancer Case Rep 3: 131. doi: 10.4172/2471-8556.1000131

Copyright: © 2017 Ekaterina K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Despite significant advances in treatment and diagnostics, cancer remains a major healthcare problem worldwide. The incidence of cancer had significantly increased globally due to the high rates of exposure to risk factors and increasing average life expectancy. It is known, that the immune system is responsible for development of a specific response against tumors. However, activated immunocompetent cells are frequently failed in their mission to reject the tumor, which leads to cancer progression and metastasis. Such failure of immune system is linked with the phenomenon of cancer recurrence, which is based on widespread of highly metastatic tumor cells with low immunogenicity. Therefore, the tumor cells acquire the ability to avoid the monitoring of immune system and become resistant to anti-cancer drugs. This specificity of the tumor cell is the key barrier to the successful treatment and management of cancer. The role of specific genes, epigenetics as well as tumor microenvironment should be further investigated and determined.